Clinical Trial Update: Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial is evaluating the safety and efficacy of tofacitinib for Chronic Granulomatous Disease with inflammatory complications. Recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Granulomatous Disease
• Inflammatory Gastrointestinal Disease
• Inflammatory Lung Disease
• Inflammatory Skin Disease

Drugs mentioned

• Tofacitinib (tofacitinib)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease | Phase 1, Phase 2 | Status: ENROLLING_BY_INVITATION